Loading…
Loading…
SQZB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SQZB and 80,000+ other tickers.
See exactly how SQZB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SQZB and 80,000+ other tickers.
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I…
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation). This transaction, which was approved by SQZ shareholders today, marks another significant milestone for STEMCELL, Canada.
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced the results for the proposals considered and voted upon by its shareholders at its special meeting on February 29, 2024 (the “Special Meeting”). The Company reported that all of the proposals submitted to its shareholders in connection with the previously announced asset sale pursuant to that certain Asset Purchase Agreement (the “Purchase Agreement”), dated December 21, 2023, ent.
WATERTOWN, Mass.WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported third quarter 2023 financial results and recent portfolio updates. “We have taken difficult, but necessary, steps to reduce our operating expenses as we explore strategic alternatives,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Officer and Member of the Board of Directors. “The Management Team and the Board firmly.
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023. “Our programs have shown a favorable safety profile and the ability to effect clinical benefit for patients,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Off.
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, today reported second quarter 2023 financial results and recent portfolio updates. “We made steady progress in the enrollment of our two clinical trials and anticipate monotherapy data readouts for each program later this year,” said Howard Bernstein, M.D., Ph.D., Interim Chief Executive Officer and Member of the Board of Directors. “We recently announced our in.